NASDAQ:AVXL
Anavex Life Sciences Corp. Stock News
$3.39
-0.0200 (-0.587%)
At Close: Apr 25, 2024
Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
12:00pm, Tuesday, 07'th Feb 2023 GlobeNewswire Inc.
Company to host a webcast today at 8:30 a.m. Eastern Time
Anavex Life Sciences Corp. (AVXL) Q1 2023 Earnings Call Transcript
10:55am, Tuesday, 07'th Feb 2023
Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q1 2023 Earnings Conference Call February 7, 2023 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisc
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
12:00pm, Thursday, 02'nd Feb 2023 GlobeNewswire Inc.
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap
Approval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi Approved
12:13pm, Monday, 30'th Jan 2023
FDA grants emergency approval of Biogen/Eisai's Leqembi (previously Lecanemab), based solely on Phase 2 trial results; Phase 3 results to be considered for final approval. Anavex Life Sciences produce
FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug
05:52pm, Friday, 20'th Jan 2023 Zacks Investment Research
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
3 Biotech Stocks Under $15 Worth a Second Look in 2023
01:00pm, Wednesday, 18'th Jan 2023 The Motley Fool
All three stocks have promising therapies that could drive revenue in the coming years.
3 Biotech Stocks Under $15 Worth a Second Look in 2023
08:00am, Wednesday, 18'th Jan 2023
All three stocks have promising therapies that could drive revenue in the coming years.
Anavex: Drug Treatments For Early Alzheimer's Disease
05:10pm, Tuesday, 17'th Jan 2023
Anavex 2-73/blarcamesine at high concentrations in early Alzheimer's disease leads to improvements in cognition and activities of daily living that are largely sustained for 148 weeks in most individu
Anavex: Despite Positive Spin, No Clarity On Anomalies
10:49am, Thursday, 12'th Jan 2023
Anavex Life Sciences Corp. presented solid-looking Alzheimer's data last month. Critics found a number of anomalies, some more real than others.
6 Favorite Biotech Bets For 2023
10:48am, Monday, 09'th Jan 2023
Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's
Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday
01:53pm, Tuesday, 03'rd Jan 2023 Benzinga
Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-marke
Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why
02:15pm, Saturday, 17'th Dec 2022 The Motley Fool
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data.
Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why
09:15am, Saturday, 17'th Dec 2022
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data.
Is Anavex Life Sciences a Buy?
02:45pm, Tuesday, 13'th Dec 2022 The Motley Fool
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's.
Is Anavex Life Sciences a Buy?
09:45am, Tuesday, 13'th Dec 2022
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's.
